Announcements Trials

Browse Landscape

Phase

Phase 3 1 Phase 2 1 Phase 1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Unspecified Adult Solid Tumor, Protocol Specific 3 Carcinoma, Hepatocellular 2 Stomach Neoplasms 1 Rectal Neoplasms 1 Pancreatic Neoplasms 1 Colorectal Neoplasms 1 Colonic Neoplasms 1 Carcinoma, Transitional Cell 1 Carcinoma, Non-Small-Cell Lung 1 Biliary Tract Neoplasms 1

Interventions

Gemcitabine 13 Cisplatin 9 Capecitabine 7 durvalumab 6 pembrolizumab 4 tremelimumab 3 S 1 (combination) 3 Nivolumab 3 AZD 6244 3 Ramucirumab 2 Fluorouracil 2 130-nm albumin-bound paclitaxel 2 vandetanib 1 trifluridine tipiracil drug combination 1 trametinib 1 tocilizumab 1 titanium silicide 1 sacituzumab govitecan 1 poly ICLC 1 futibatinib 1 fludarabine 1 cemiplimab 1 binimetinib 1 aflibercept 1 Tegafur 1 TAS-116 1 Psilocybin 1 Peptides 1 Oxaliplatin 1 NUC-1031 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 1 × Biliary Tract Neoplasms × Tegafur × Clear all

NCT03162510 2022-04-07

SOLAR

National Health Research Institutes, Taiwan

Phase 1 Completed

Gastrointestinal

Biliary Tract Neoplasms, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡